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DVT: A New Era in Anticoagulant Therapy
Indications for Catheter-Directed Thrombolysis in the
Management of Acute Proximal Deep Venous Thrombosis
Benjamin O. Patterson, Robert Hinchliffe, Ian M. Loftus, Matt M. Thompson, Peter J.E. Holt
Abstract—Deep vein thromboses (DVTs) cause significant morbidity and mortality in the general population. Oral anticoag-
ulation therapy may reduce thrombus propagation but does not cause clot lysis and therefore does not prevent postthrombotic
syndrome (PTS). Catheter-directed thrombolysis (CDT) can be used to treat DVTs as an adjunct to medical therapy, but there
is no consensus defining exact indications. Current evidence suggests that CDT can reduce clot burden and DVT recurrence
and consequently prevents the formation of PTS compared with systemic anticoagulation. Appropriate indications include
younger individuals with acute proximal thromboses, a long life expectancy, and relatively few comorbidities. Limb-
threatening thromboses may also be treated with CDT, although the subsequent mortality remains high. A number of
randomized controlled trials are currently under way comparing the longer-term outcomes of CDT compared with
anticoagulation alone. Initial reports suggest that venous patency and valvular function are better maintained after CDT. The
effectiveness of combined pharmacomechanical thrombectomy and the role of vena cava filters need to be investigated further
before strong recommendations can be made. The reported short-term outcomes following catheter-based intervention for
DVT are encouraging in selected patients. Further evidence is required to establish long-term benefits and cost-effectiveness.
(Arterioscler Thromb Vasc Biol. 2010;30:669-674.)
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Deep vein thrombosis (DVT) is the third most commoncardiovascular pathology, after coronary artery disease
and stroke. In the United Kingdom, 1 in 1000 people develop
DVT each year. It is likely that the incidence of DVT will
increase in the future because of an aging population and
increasing exposure to risk factors for DVT, such as hospital
admissions, oral contraceptives, long-distance travel, and
obesity. A European group estimated that there are almost
half a million cases of DVT, 300 000 cases of pulmonary
embolism, and 370 000 venous thromboembolism related
deaths across 6 European Union countries per annum among
inpatients. It must be presumed that many of these events
could have been prevented.1
This article accompanies the DVT Series that
was published in the March 2010 issue.
Postthrombotic syndrome (PTS) is a relatively common
and highly significant sequel of DVT. Eighty percent of
symptomatic DVTs are above the knee (proximal), with a
cumulative incidence of PTS of 50% 2 years post-DVT.2
Severe PTS is reported in 50% of cases, and leg ulceration is
present in up to 10% of patients. These conditions lead to
reduced quality of life and disability. The mean age of
patients affected is 56, and more than 50% of patients are of
working age, meaning that DVT is costly to society in
general.3 The cost of managing venous ulcers in the United
Kingdom alone is £400 million per year.
PTS is caused by chronic venous hypertension secondary
to venous reflux, venous obstruction, and valvular dysfunc-
tion. This manifests clinically as a painful, swollen, heavy leg
and venous claudication. At the most severe end of the
spectrum, PTS is associated with venous ulceration.4
PTS can be objectively defined using the Villalta score, which
examines the severity of various clinical features.4 Recent
research has shown that quality of life among patients with PTS
is poorer than that among patients of similar age with other
chronic conditions, such as arthritis, chronic lung disease, or
diabetes. Severe PTS leads to such a poor quality of life that it
is comparable to experiencing angina, cancer, or congestive
heart failure.3
In addition to PTS and ulceration, some patients with proxi-
mal DVTs will develop pulmonary embolism. Patients with 1
DVT are also at increased risk of recurrence. An uncommon but
significant complication of DVT is phlegmasia caerulea dolens.
This is caused by thrombosis at a capillary level as a conse-
quence of venous stasis and appears as a swollen, cyanotic limb.
Venous infarction and compartment syndrome and limb loss
may follow, and the associated mortality is high.5
Treatment Modalities
It has been shown that anticoagulation for 3 to 6 months and
the use of graduated compression stockings for 2 years
significantly reduces the incidence of PTS.2 Despite this, at 2
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years after proximal DVT, up to 50% of patients will have
evidence of PTS.6 A reason for this is that oral anticoagula-
tion does not precipitate thrombolysis but stops thrombus
propagation and protects against recurrence.7 It is thought that
chronic venous hypertension secondary to valvular destruc-
tion leads to PTS. Therefore, if valvular function can be
effectively preserved through early clot lysis, there might be
benefits in terms of a reduced incidence of PTS.
Systemic thrombolysis had been investigated in trials to
achieve this early lysis, but it was associated with unaccept-
ably high rates of serious bleeding complications, such as
retroperitoneal hematoma and intracranial hemorrhage, with
relatively modest rates of thrombus clearance.8–10 Catheter-
directed thrombolysis (CDT) involves a more localized de-
livery of thrombolytic agents directly into the thrombus. This
may be more effective in achieving local resolution and
restoring venous patency while significantly reducing the
risks of bleeding complications.
A Cochrane review compared thrombolysis with standard
anticoagulation across 12 randomized controlled trials
(RCTs) comprising 700 patients. The majority of these
studies included only patients treated with systemic
thrombolysis. Clot lysis was seen more frequently in early
(relative risk, 4.14; 95% CI, 1.22 to 14.01) and late (relative
risk, 2.71; 95% CI, 1.84 to 3.99) follow-up. The incidence of
PTS was reduced significantly (relative risk, 0.66; 95% CI,
0.47 to 0.94).11 A 50% reduction of relative risk (although not
statistically significant) in the formation of lower limb ulcers
was demonstrated. Bleeding complications were significantly
higher (relative risk, 1.73; 95% CI, 1.04 to 2.88). The
suggestion was that thrombolysis offered potential advan-
tages but that indications were not clearly defined. In addition
to 2 RCTs, there are several institutional cases series report-
ing the use of CDT and mechanical thrombectomy (Table 1).
They display considerable variation in design and the com-
bination of therapies used, but all convey the message that
venous patency can often be restored in the short and long
terms with catheter-delivered therapy. In addition, significant
improvements in quality of life have also been demonstrated.6
Defining which groups of patients will benefit most from the
use of this newer technology is one of the major challenges
facing exponents of this technique.
Achieving Venous Patency
A 3-point scale has been proposed to define outcomes of
therapy for DVT (Table 2),12 with grades II and III signifying
at least 50% luminal patency postlysis. This is classed as a
satisfactory therapeutic outcome. A recent report describing
Table 1. A Summary Previous Trials Investigating the Role of Catheter Delivered Therapy for DVT
Study (Year) Design
Limbs
Treated Pathology Arms Agent Short-Term Patency Long-Term Patency
Bjarnason et al
(1997)25
Institution series 87 Acute iliofemoral DVT CDT (87)
angioplastystentPMT
Urokinase Immediate: 69 (79%), iliac, 86%;
femoral, 63%
1 year: iliac, 63% primary, 78%
secondary; femoral, 40%
primary, 51% secondary
Mewissen et al
(1999)24
National registry
data
303 Acute and chronic
suprapopliteal
CDT Urokinase Immediate: grade III in 96 (31%),
II in 162 (52%), I in 54 (17%)
1 year: 181 (60%)
Gandini et al
(1999)33
Institution series 8 Iliocaval thrombosis PMT None Immediate: 6 (75%) 2 years: 6 (75%)
Elsharawy et al
(2002)34
Single blind RCT 35 Iliofemoral DVT 10 days CDT (18),
Anticoagulation alone (17)
Streptokinase 1 week: CDT 11 (61%), control 0
(0%)
6 months: CDT, 2 (13%);
control, 2 (12%)
Jackson et al
(2005)35
Institution series 28 Acute supra popliteal DVT
(4 had symptoms 14 days)
CDTstentingPMT Immediate: 5 (18%) complete
lysis, 20 (72%) partial
1 year: 22 (80%)
Lin et al
(2006)36
Retrospective
comparison of
CDT and PMT
98 Acute symptomatic lower
limb DVT
CDT (46), PMT (52) CDT: 32 (75%) complete, 14
(25%) partial; PMT: 39 (75%)
complete, 13 (25%) (Primary
assisted)
1 year: CDT, 29 (64%); PMT, 35
(68%)
Protack et al
(2007)12
Institution series 69 Lower extremity DVT CDT (27), PMT (12), both
(30)
Immediate: grade III in 46 (67%),
II in 19 (26%), I in 4 (6%)
2 years: 57 (83%) freedom from
rethrombosis
Rao et al
(2009)32
Institution series 43 Symptomatic iliofemoral DVT
(19, 14 days)
CDTPMT r-TPA Immediate: grade III, III lysis in
41 (95%)
Not reported
Shi et al
(2009)37
Institution series 16 Massive lower limb DVT CDTPMTIVC filter Urokinase Immediate: grade III and III lysis
in 14 (89%), I in 2 (11%)
Follow-up:* 12 (75%)
Baekgaard et
al (2009)14
Institution series 103 DVT 14 days, open distal
popliteal vein
CDTstockings
(103)stent (57)
r-TPA 1 week: 95/103 (92%) 6 years: 84 (82%) mean
follow-up 50 months
Enden et al
(2009)13
Open
multicenter RCT:
short-term
report
103 Iliofemoral DVT 21 days
and symptoms
CDTanticoagulation (50),
anticoagulation alone (53)
r-TPA Immediate: grade III in 24, II in
20 for CDT group
6 months: 32 (64%) of CDT
group vs 19 (36%) of control
All patients were treated postprocedure with standard anticoagulation unless otherwise stated. Grade III lysis, complete; grade II lysis, 50% to 90%; grade I lysis,
50%.
*Timing not available.
Table 2. Grade of Lysis Following Treatment of DVT (Adapted
From Protack et al12)
Grade of lysis
Grade I 50% lysis
Grade II 50–99% lysis
Grade III Complete lysis
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short-term follow-up results from the ongoing Norwegian
CaVenT randomized control trial showed favorable patency
rates when CDT was compared with anticoagulation and
compression stockings.13 Grade II–III lysis was achieved in
40% of patients immediately postprocedure. After 6-months,
iliofemoral patency was found in 64% of the CDT group and
compared with 35% of the control group, giving an absolute
risk reduction of 28% (95% CI: 9.7% to 46.7%; P0.004).
Venous obstruction was present in 20% of the CDT group
and 49% of controls, representing an absolute risk reduction
of 29% (95% CI: 20.0% to 38.0%; P0004). Recently, a
Scandinavian group has reported 50-month follow-up data on
of a series of 103 limbs treated by DCT in a group of 101
highly selected patients. More than 82% of patients had
patent veins with competent valves and no skin symptoms.14
Timing of CDT
The success of venous recanalization, preservation of valve
function, and symptom relief may depend on the timing of
therapy postthrombosis. These factors influence effectiveness
of intervention and the subsequent incidence of PTS.
Freshly formed thromboses respond better to thrombolysis
than established, organized thromboses. It has been sug-
gested that 10 days may be the optimal interval from onset
of symptoms during which to instigate treatment15; how-
ever, the ATTRACT trial in the United States has used 14
days and the CaVenT trial has used 21 days as the cut-off for
recruitment.16,17 This interval requires further definition
through the results of these trials to determine the optimal
time frame for intervention that will prevent valvular destruc-
tion and venous hypertension, which may result in an increase
of the likelihood of longer-term sequalae.18–20
Percutaneous Mechanical Thrombectomy
Combining CDT and percutaneous mechanical thrombec-
tomy (PMT) devices has been attempted to try to improve
early mechanical thrombus removal and promote lysis of
remaining clot. Several devices exist to perform PMT, but the
optimum design and outcomes are not known, despite en-
couraging early reports and case series. Devices include
rotating sinusoidal dispersion wires (Trellis-8, Bacchus Vas-
cular Inc, Santa Clara, CA); pulsatile saline jets (Angiojet,
Possis Medical Inc, Minneapolis, MN); and low-energy
high-frequency ultrasound (Ekos, Bothell, WA).21 A series of
43 patients with DVTs undergoing PMT within an average of
14 days of symptom onset recently reported short-term results
with successful lysis 63% of clots after 1 session of PMT
(greater than 50% clot lysis). One-third of patients had iliac
stents deployed in conjunction with mechanical therapy.
Freedom from DVT recurrence and reintervention was main-
tained in 95% of patients after 9 months. The ATTRACT trial
will report on the merits of combined therapy in the future.16
Potential Complications
Many of the reported complications following CDT were
related to hemorrhage, as may be expected. The US National
Venous Registry reported infrequent but severe peri- and
postprocedural complications that included intracranial hem-
orrhage (1%); retroperitoneal hematoma (1%); and muscu-
loskeletal, genitourinary, and gastrointestinal bleeds (3%).22
Most incidents of bleeding were relatively minor, such as that
associated with the access site. Catheterization of access
veins under ultrasound guidance has been shown to reduce
these complications by avoiding multiple vessel punctures.23
In addition, aiming for the minimum infusion time to achieve
the best results and minimizing the dose of thrombolytic
agent reduces both local and systemic bleeding complica-
tions. The mechanical thrombectomy device might play a role
in achieving this balance.
Some centers have reported an increased incidence of
pulmonary embolism following percutaneous treatments, but
this has not been supported by registry reports or trials
data.24,25 Finally, with regard to mortality, the reported rate of
mortality for patients undergoing CDT is less than 1%.
Currently, patients are highly selected for CDT, so the true
postprocedural mortality is unknown. This said, it is likely to
remain less than 1% in routine practice.
Controversies
The practice of CDT remains variable between centers. The
choice of thrombolytic agent, the use of adjunctive venous
stenting, and inferior vena cava (IVC) filters are areas in
which this variability becomes most apparent.
Endogenous serine protease inhibitors such as urokinase
and recombinant tissue plasminogen activator (r-TPA) have
replaced streptokinase as the agent of choice in systemic
thrombolysis. r-TPA is the most effective and is likely to be
associated with fewer side effects. Consequently, the major
RCTs under way are using Alteplase in their protocols (Table 3),
Table 3. A typical Protocol for Performing Thrombolysis in
Cases of DVT
Patient is identified; if on LMWH,* this is stopped for 8 hours
Oral anticoagulants are stopped, ensuring international normalized ration
(INR) 1.5
5000-U bolus of UFH administered
Infusion of UFH at 15 U/kg, keeping activated partial thromboplastin time
(APTT) at 1.2–1.7 times normal
Appropriate venous access obtained under ultrasound guidance with local
anesthetic
Wire/catheter is introduced above proximal thrombus, and venography is
performed
20 mg of Alteplase administered in 500 mL of 0.9% NaCl at a rate of 0.01
mg/kg/hour to a maximum of 20 mg in 24 hours
During infusion, observation of hemodynamic stability and puncture site is
performed
Clotting studies are performed daily with daily venography
Maximum time of therapy should be 96 hours
Balloon angioplasty/placement of venous stents may be performed if
necessary
Catheters are removed, and manual pressure is used to control bleeding
Pressure dressing applied for a further 2 hours, with an additional dose of
LMWH given 1 hour after catheters are removed
Anticoagulation is then established
Adapted from CaVent trial methodology.17
LMHW, low–molecular weight heparin, UFH, unfractionated heparin.
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and this is being used with increasing regularity in clinical
practice.
The use of IVC filters as an adjunct to CDT remains
controversial. Many series report their use in selected cases.
Situations where they may prove useful include those in
which standard indications would apply, such as a patient
developing a thrombosis while on effective anticoagulation or
the presence of a contraindication to anticoagulation. Filters
should not be used routinely, as CDT has not been shown to
increase the rate of pulmonary embolism (PE). There remains
insufficient evidence to determine whether IVC filters should
be used for free-floating thrombus or thrombus extending into
the IVC. We recommend that use of filters be decided
through multidisciplinary team discussion on an individual
case-by-case basis, and where possible, temporary filters
should preferentially be used. In practice, we rarely use them.
Endovascular venous stent placement in conjunction with
thrombolysis may improve patency rates in selected cases,
particularly if abnormal anatomy is the underlying cause of
DVTs. May-Thurner syndrome is the most common of these
conditions; in this syndrome, the left common iliac vein is
compressed by the overlying right common iliac artery,
leading to both extrinsic compression and vessel damage
because of the repeated trauma of the arterial pulse. Other
causes include pelvic tumors, osteophytes, chronic urinary
retention, iliac artery aneurysms, endometriosis, pregnancy,
and uterine masses.26
A review of case series with 5 or more patients revealed an
initial technical success rate of 87% to 100% and 1 year
patency of between 80% and 100% (Table 4). Patent venous
outflow at 2 years has been reported after combined CDT and
stenting in 1 study.27–29 In 1 small series of May-Thurner
patients, all those treated by CDT alone had evidence of
rethrombosis on follow-up venogram, whereas only 11% of
patients treated with CDT and stenting developed stent
occlusion.28,30 Further research has shown that the use of
thrombolysis without stent placement, in cases of May-
Thurner, can lead to restenosis in up to 75% of patients in the
short term.28,31 It should be noted that venous stents can
induce long-term DVT recurrence because of low luminal
flow rates. This may outweigh the apparent short-term
benefits, but additional data are required. At present, not
enough data exist to determine the exact indications for
deployment of stents, but once again, the results of the
randomized trials appear critical to provide clear answers.
Cost-Effectiveness and Quality of Life
Systemic anticoagulation with subcutaneous low–molecular
weight heparin is easy to initiate, relatively convenient for
patients, and inexpensive. As anticoagulation is still required
after CDT, the procedural costs associated with CDT along
with an inpatient admission will always be greater than for
the outpatient management of oral anticoagulation alone.
This apparent drawback must be considered in the context
of the economic burden of PTS and venous ulceration, not
simply because of the utilization of hospital and community
healthcare resources (which cost more than £400 million per
year in the United Kingdom alone) but also in terms of lost
opportunity costs. One study suggested that 81% of patients
suffered loss of financial productivity post-DVT. This is of
considerable interest in light of the fact that more than 50% of
patients with proximal DVT are of working age.15
Health-related quality of life in patients receiving CDT has
been shown to be improved in comparison with those treated
with systemic anticoagulation alone at 16 and 22 months
posttreatment.32 In addition, patients with proximal DVTs
treated by CDT reported better functional scores and fewer
symptoms of PTS than those undergoing systemic anticoag-
ulation.12 These findings will be of importance in the cost-
effectiveness analyses of the ongoing randomized trials.
Recommendations for Management
This review of the relevant literature suggests CDT can
achieve superior clot lysis in the acute setting, with better
long-term venous patency rates in comparison with anticoag-
Table 4. A Summary of Series Reporting Use of CDT and Venous Stent Placement in Patients With May-Thurner Syndrome
Study (Year) N Pathology Therapy Initial Technical Short-Term Patency Long-Term Patency
Major Adverse
Events
O’Sullivan et al (2000)38 39 M-T with DVT (19) and
symptomatic (20)
Urokinase and stent
(35 stented)
34/39 (87%) 90% at 1 year of
stented patients
Not reported 2
Patel et al (2000)39 10 M-T with acute iliofemoral DVT Urokinase and stent 10/10 (100%) 10/10 (100%) at 1 year Not reported 0
Heijmen et al (2001)40 6 M-T, symptomatic Angioplasty and stent 6/6 (100%) 5/6 (83%) at 1 year Not reported 0
Kwak et al (2005)29 22 M-T with DVT (6 other causes
of venous compression)
Urokinase and stent 26/27 (96%) Primary 95% Secondary
100% At 1 year
Primary 95% Secondary
100% At 2 years
2
Kim et al (2006)28 21 M-T with DVT 18 urokinase and stent;
3 stent alone
20/21 (95%) 18/21 (85%) at 6
months
Not reported 1
Husmann et al (2007)30 11 M-T with DVT Thrombectomy and
stenting
11/11 (100%) 10/11 (91%)* up to
22 months
0
M-T, May-Thurner syndrome.
*Assisted primary patency rate.
Table 5. Possible Indications for DVT Thrombolysis
Extensive thrombosis with high risk of pulmonary embolism
Proximal DVT (iliofemoral or femoral vein)
Threatened limb viability
Underlying predisposing anatomic anomaly
Good physiological reserve (18–75 years old)
Life expectancy over 6 months
Recent onset of symptoms (14 days)
Absence of contraindications to thrombolysis
672 Arterioscler Thromb Vasc Biol April 2010
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ulation alone. This may avoid the clinical sequelae of PTS
and venous ulceration. The indications for CDT are based on
a number of small RCTs, registry data, and institutional series
and a variety of expert opinions.
Current guidelines from the American College of Chest
Physicians suggest that CDT should be used in those with life
expectancy 1 year, good functional status, extensive il-
iofemoral thrombosis, and presenting soon after the onset of
symptoms14 days (level 2B evidence). The guidelines also
advocate the use of venous angioplasty and stenting in the
presence of reversible causes of thrombosis and discuss the
efficacy of dual therapy with pharmacomechanical therapy.12
Those most likely to benefit from CDT (Table 5) are
individuals with a long life expectancy, as the reductions in
PTS and ulceration are likely to be the most important
benefits. These outcomes have a measurable incidence at 2
years postthrombosis, and so the differences in outcomes
between medically treated patients and those with CDT might
be most easily interpreted at this stage. Those patients of
working age are likely to derive the most benefits at the
lowest risk of intervention.
Higher rates of PTS are seen with more proximal thrombi
and in the absence of contraindications, CDT should be
considered in these cases. This would include both iliofem-
oral and femoral vein thromboses. Adjunctive venous stent-
ing is appropriate in cases in which there is an underlying
anatomic abnormality.
Unfortunately, some groups of patients with proximal
thrombosis would currently be excluded from management
by CDT using currently published criteria (Table 6). This
may include trauma victims or patients who have undergone
recent surgery, although these patients may stand to gain most
significantly from effective treatment of extensive thrombo-
sis. The role for mechanical thrombectomy devices might lie
in these patient subgroups. In individual cases, a combination
of the focused delivery of thrombolytic agent with or without
the addition of mechanical therapy may be not only safe but
also highly effective.
Oncology patients are at high risk of thromboembolism,
and the mortality in this group is significantly higher than that
of the general population following DVT. Life expectancy
and the risk of hemorrhage (ie, likelihood of brain or liver
metastases) must be considered and assessed before CDT. A
full assessment would realistically include a current head and
chest-abdomen-pelvis computed tomography scan to identify
metastases. The current inclusion criteria for CDT may need to
be broadened if more patient groups such as this are to benefit,
but this is not likely to occur until the full benefit of CDT has
been quantified in more selected subgroups of patients.
Given the high associated mortality of phlegmasia caerulea
dolens and the lack of an effective alternative, CDT is
probably justified in this patient group, despite a high
mortality due to the underlying disease, and may lead to
effective limb salvage in up to 100% of cases.12
Extensive, free-floating or IVC thromboses may be at high
risk of causing pulmonary embolism. Timely reduction of
clot burden using CDT would seem to offer a better chance of
avoiding such events than simply relying on systemic anti-
coagulation to prevent their propagation. Whether IVC filters
should be used remains an area of considerable debate.
The outcome of the CaVenT, ATTRACT, and the pro-
posed United Kingdom–based RCTs should provide further
guidance regarding exclusion and inclusion criteria for CDT
(Table 7). Detailed health-economic analyses of the use of
CDT and thrombectomy devices are required to establish the
cost-effectiveness of this treatment. Finally, encouraging
results regarding CDT in the management of DVTs should
not detract from meticulous DVT prophylaxis in all at-risk
patients.
Conclusions
Venous thromboembolism is common and has a significant
socioeconomic impact. The present therapeutic strategy in the
form of oral anticoagulation does not prevent the PTS and
venous ulceration, even when combined with elastic com-
pression stockings.
CDT is effective in achieving clot lysis in acute thrombo-
sis, and this may help to prevent PTS and subsequent
ulceration. The incidence of serious complications is accept-
able following these procedures. Patient selection is of
importance to achieve maximum benefit at the lowest risk,
Table 6. Contraindications for Thrombolysis
Bleeding diathesis/thrombocytopenia
Organ specific bleeding risk (eg recent myocardial infarction, cerebrovascular
accident, gastrointestinal bleed, surgery, or trauma)
Renal or hepatic failure
Malignancy (ie brain metastases)
Pregnancy
Table 7. A Summary of Major Ongoing Trials Investigating the Role of Catheter Delivered Therapy for DVT
Study Design N Pathology Arms Therapy Primary End Secondary End Reporting
CaVenT17 Open RCT 200 Iliofemoral DVT present
for 21 days
CDT/conventional
anticoagulation
r-TPA 6 month patency/
incidence of PTS
at 24 months
Doppler patency/
QOL*/cost
effectiveness
Short-term patency reported
Dec 2009; complete 2017
ATTRACT16 Open multicenter
RCT
692 Iliac, common femoral
and femoral vein; DVT
14 days
PMTCDT/
conventional
anticoagulation
r-TPA Incidence of PTS
at 24 months
Symptom
resolution/adverse
events/QOL
4.5 years after commencing
UK RCT
(proposed)
Assesor-blinded
multicenter RCT
400 Proximal DVT 14 days CDT/conventional
anticoagulation
compression
stockings
r-TPA Incidence of PTS
at 24 months
Leg ulceration/
QOL/cost-
effectiveness
Awaiting funding decision
QOL, quality of life.
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and the reports of several ongoing RCTs are awaited to help
define who will benefit most. Based on these trial results, the
cost-effectiveness of CDT will be effectively determined.
This is needed before the routine use of CDT can be
advocated.
Disclosures
None.
References
1. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG,
Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E,
Samama MM, Spannagl M. Venous thromboembolism (VTE) in Europe:
the number of VTE events and associated morbidity and mortality.
Thromb Haemost. 2007;98:756–764.
2. Prandoni P, Lensing AW, Prins MH, Frulla M, Marchiori A, Bernardi E,
Tormene D, Mosena L, Pagnan A, Girolami A. Below-knee elastic
compression stockings to prevent the post-thrombotic syndrome: a ran-
domized, controlled trial. Ann Intern Med. 2004;141:249–256.
3. Kahn SR, Shbaklo H, Lamping DL, Holcroft CA, Shrier I, Miron MJ,
Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L,
Johri M, Ginsberg JS. Determinants of health-related quality of life
during the 2 years following deep vein thrombosis. J Thromb Haemost.
2008;6:1105–1112.
4. Kahn SR, Partsch H, Vedantham S, Prandoni P, Kearon C, on behalf of
the Subcommitee on the Control of Anticoagulation of the Scientific and
Standardization Committee of the International Society on Thrombosis
and Haemostasis. Definition of post-thrombotic syndrome of the leg for
use in clinical investigations: a recommendation for standardization.
J Thromb Haemost. 2009;7:879–838.
5. Weaver F, Meacham P, Adkins R, Dean R. Phlegmasia cerulea dolens:
therapeutic considerations. South Med J. 1998;81:306–312.
6. Kahn S, Ginsberg J. The post-thrombotic syndrome: current knowledge,
controversies, and directions for future research. Blood Rev. 2002;16:
155–165.
7. Buller H, Agnelli G, Hull R, Hyers TM, Prins MH, Raskob GE. Anti-
thrombotic therapy for venous thromboembloic disease: the Seventh
ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest.
2004;126:401S–428S.
8. Meissner AJ, Misiak A, Ziemski JM, Scharf R, Rudowski W, Huszcza S
Kucharski W, Wisławski S. Hazards of thrombolytic therapy in deep vein
thrombosis. Br J Surg. 1987;74:991–993.
9. Comerota AJ, Aldridge SC. Thrombolytic therapy for deep venous throm-
bosis: a clinical review. Can J Surg. 1993;36:359–364.
10. Schweiter J, Kirch W, Koch R, Elix H, Hellner G, Forkmann L, Graf A.
Short and long-term results after thrombolytic treatment of deep venous
thrombosis. J Am Coll Cardiol. 2000;36:1343.
11. Watson L, Armon M. Thrombolysis for acute deep venous thrombosis.
Cochrane Database Syst Rev. 2007;18:Art No. CD002783.
12. Protack C, Bakken A, Patel N, Saad W, Waldman D, Davies M.
Long-term outcomes of catheter directed thrombolysis for lower
extremity deep venous thrombosis without prophylactic inferior vena
cava filter placement. J Vasc Surg. 2007;45:992–997.
13. Enden T, Klow NE, Sandvik L, Slagsvold CE, Ghanima W, Hafsahl G
Holme PA, Holmen LO, Njaastad AM, Sandbaek G, Sandset PM.
CaVenT study group. Catheter-directed thrombolysis vs. anticoagulant
therapy alone in deep vein thrombosis: results of an open randomized,
controlled trial reporting on short-term patency. J Thromb Haemost.
2009;7:1268–1275.
14. Baekgaard N, Broholm R, Just S, Jorgensen M, Jensen L. Long-term
results using catheter-directed thrombolysis in 103 lower limbs with acute
iliofemoral venous thrombosis. Eur J Vasc Endovasc Surg. 2010;39:
112–117.
15. Kearon C, Kahn S, Agnielli G, Goldhaber S, Raskob G, Comerota A.
Antithrombotic therapy for venous thromboembolic disease: Am College
of Chest Physicians evidence based clinical practice guidelines (8th
edition). Chest. 2008;133:454S–545S.
16. Comerota AJ. The ATTRACT trial: rationale for early intervention for
iliofemoral DVT. Perspect Vasc Surg Endovasc Ther. 2010 Jan 3 [E-pub
ahead of print].
17. Enden T, Sandvik L, Klow N, Hafsahl G, Holme PA, Holman LO
Ghanima W, Njaastad AM, Sandbaek G, Slagsvold CE, Sandset PM.
Catheter-directed venous thrombolysis in acute iliofemoral vein throm-
bosis: the CaVenT study: rationale and design of a multicentre, ran-
domized controlled, clinical trial (NCT00251771). Am Heart J. 2007;154:
808–814.
18. Segal J, Streiff M, Hofmann L, Thornton K, Bass E. Management of
venous thromboembolism: a systematic review for a practice guideline.
Ann Intern Med. 2007;146:211–222.
19. Meissner M. Thrombolytic therapy for acute deep vein thrombosis and
the venous registry. Rev Cardiovasc Med. 2002;3:S53–S60.
20. Mewissen M. Catheter-directed thrombolysis for lower extremity deep
vein thrombosis. Tech Vasc Interv Radiol. 2001;4:111–114.
21. McLafferty R. Endovascular management of deep venous thrombosis.
Perspect Vasc Surg Endovasc Ther. 2008;20:87–91.
22. Strandness D Jr, Langlois Y, Cramer M, Randlett A. Long-term sequelae
of acute venous thrombosis. JAMA. 1983;250:1289–1292.
23. Comerota A, Schmieder F. Intraoperative lytic therapy: agents and
methods of administration. Semin Vasc Surg. 2001;14:132–142.
24. Mewissen M, Seabrook G, Meissner MH, Cynamon J, Labropoulos N,
Haughton SH. Catheter-directed thrombolysis for lower extremity deep
venous thrombosis: report of a national multicenter registry. Radiology.
1999;211:39–49.
25. Bjarnason H, Kruse JR, Asinger DA, Nazarian GK, Dieta CA Jr, Caldwell
MD Key NS, Hirsch AT, Hunter DW. Iliofemoral deep venous throm-
bosis: safety and efficacy outcome during 5 years of catheter-directed
thrombolytic therapy. J Vasc Interv Radiol. 1997;8:405–418.
26. Kibbe M, Ujiki M, Goodwin A, Eskandari M, Yao J, Matsumura J. Iliac
vein compression in an asymptomatic patient population. J Vasc Surg.
2004;39:937–943.
27. Heniford B, Senler S, Olsofka J, Carrillo E, Bergamini T. May-Thurner
syndrome: management by endovascular surgical techniques. Ann Vasc
Surg. 1998;12:482–486.
28. Kim J, Choi D, Guk Ko Y, Park S, Jang Y, Lee do Y. Percutaneous
treatment of deep vein thrombosis in May-Thurner syndrome. Cardiovasc
Intervent Radiol. 2006;29:571–575.
29. Kwak H, Han Y, Lee Y, Jin G, Chung G. Stents in common iliac vein
obstruction with acute ipsilateral deep thrombosis: early and late results.
J Vasc Interv Radiol. 2005;16:815–822.
30. Husmann M, Heller G, Kalka C, Savolainen H, Do D, Schmidli J.
Stenting of common iliac vein obstructions combined with regional
thrombolysis and thrombectomy in acute deep vein thrombosis. Eur J
Vasc Endovasc Surg. 2007;34:87–91.
31. Burroughs K. New considerations in the diagnosis and therapy of deep
vein thrombosis. South Med J. 1999;92:517–520.
32. Rao A, Konig G, Leers SA, Cho J, Rhee RY, Makaroun MS, Chaer RA.
Pharmacomechanical thrombectomy for iliofemoral deep vein throm-
bosis: an alternative in patients with contraindications to thrombolysis.
J Vasc Surg. 2009;50:1092–1098.
33. Gandini R, Maspes F, Sodani G, Masala S, Assegnati G, Simonetti G.
Percutaneous ilio-caval thrombectomy with the Amplatz device: pre-
liminary results. Eur Radiol. 1999;9:951–958.
34. Elsharawy M, Elzayat E. Early results of thrombolysis vs. anticoagulation
in iliofemoral venous thrombosis: a randomised clinical trial. Eur J Vasc
Endovasc Surg. 2002;24:209–214.
35. Jackson L, Wang X, Dudrick S, Gersten G. Catheter directed
thrombolysis and/or thrombectomy with selective endovascular stenting
as alternatives to systemic anticoagulation for treatment of acute deep
vein thrombosis. Am J Surg. 2005;190:864–868.
36. Lin P, Zhou W, Dardik A, Mussa F, Kougias P, Hedayati H. Catheter-
direct thrombolysis versus pharmacomechanical thrombectomy for
treatment of symptomatic lower extremity deep venous thrombosis. Am J
Surg. 2006;192:782–788.
37. Shi H, Huang Y, Shen T, Xu Q. Percutaneous mechanical thrombectomy
combined with catheter-directed thrombolysis in the treatment of symp-
tomatic lower extremity deep venous thrombosis. Eur J Radiol. 2009;71:
350–355.
38. O’Sullivan GJ, Semba CP, Bittner CA, Kee ST, Razavi MK, Sze DY,
Dake MD. Endovascular management of iliac vein compression (May-
Thurner) syndrome. J Vasc Interv Radiol. 2000;11:823–836.
39. Patel NH, Stookey KR, Ketcham DB, Cragg AH. Endovascular man-
agement of acute extensive iliofemoral deep venous thrombosis caused by
May-Thurner syndrome. J Vasc Interv Radiol. 2000;11:1297–1302.
40. Heijmen RH, Bollen TL, Duyndam DA, Overtoom TT, Van Den Berg JC,
Moll FL. Endovascular venous stenting in May-Thurner syndrome.
J Cardiovasc Surg (Torino). 2001;42:83–87.
674 Arterioscler Thromb Vasc Biol April 2010
 by guest on January 13, 2014http://atvb.ahajournals.org/Downloaded from 
